Pope L, Paterson P Y, Miller S D
Department of Microbiology-Immunology, Northwestern University Medical School, Chicago, IL 60611.
J Neuroimmunol. 1992 Apr;37(3):177-89. doi: 10.1016/0165-5728(92)90002-3.
The efficacy of antigen-specific immunoregulation as a treatment for the efferent limb of an autoimmune disease was tested in a rat model of adoptive experimental autoimmune encephalomyelitis (EAE). Lewis rats receiving 4-5 x 10(7) guinea pig (GP) myelin basic protein (MBP)-activated lymph node T cell blasts from GPMBP/CFA sensitized donors routinely show clinical signs of disease 5-6 days post transfer. Intravenous injection of GPMBP coupled to syngeneic splenocytes using the chemical cross-linker carbodiimide was effective in completely abrogating the expression of clinical EAE in rats that received MBP-specific T cells 2 days previously. Partial inhibition was also observed in rats injected as early as day 0 (the same day as MBP-specific T cell transfer) and as late as 1 day prior to the onset of clinical signs (days 4-5 post transfer). Unresponsiveness was shown to be dose-dependent, dependent on the route of injection of the neuroantigen-coupled splenocytes, and was antigen-specific. Splenocytes coupled with GP or rat MBP (which are identical within the major encephalitogenic GP68-86 Lewis rat determinant with the exception of the residue at position 80) were equally efficient at eliminating disease expression in recipients of GPMBP-specific T cells. In contrast, splenocytes coupled with bovine or rabbit MBP (which differ significantly from GPMBP within the 68-86 region) had no inhibitory effect. The antigen specificity of the tolerance induction was also illustrated by the fact that splenocytes coupled with GP68-86, but not those coupled with the truncated GP68-84 peptide, induced profound unresponsiveness. Interestingly, de novo antigen processing by the antigen-coupled cells did not appear to be necessary as the inclusion of antigen processing inhibitors had no effect on inhibition of disease. However, the use of the carbodiimide coupling reagent was critical for the induction of unresponsiveness as essentially equivalent amounts of 125I-labelled MBP were bound in its presence or absence, but only splenocytes incubated in the presence of both MBP and carbodiimide inhibited clinical expression of disease. Antigen-specific tolerance is thus an effective means of inhibiting expression of clinical disease in the rat EAE model, and a powerful tool for determining the fine epitope specificity of encephalitogenic T cells.
在过继性实验性自身免疫性脑脊髓炎(EAE)大鼠模型中,测试了抗原特异性免疫调节作为自身免疫性疾病传出支治疗方法的疗效。接受来自GPMBP/CFA致敏供体的4-5×10⁷只豚鼠(GP)髓鞘碱性蛋白(MBP)激活的淋巴结T细胞母细胞的Lewis大鼠,在转移后5-6天通常会出现疾病的临床症状。使用化学交联剂碳二亚胺将GPMBP与同基因脾细胞偶联后静脉注射,对于2天前接受MBP特异性T细胞的大鼠,能有效完全消除临床EAE的表现。在最早于第0天(与MBP特异性T细胞转移同一天)以及最晚在临床症状出现前1天(转移后4-5天)注射的大鼠中也观察到部分抑制作用。无反应性表现为剂量依赖性,取决于神经抗原偶联脾细胞的注射途径,且具有抗原特异性。与GP或大鼠MBP偶联的脾细胞(除第80位残基外,在主要致脑炎性GP68-86 Lewis大鼠决定簇内相同)在消除GPMBP特异性T细胞受体的疾病表现方面同样有效。相比之下,与牛或兔MBP偶联的脾细胞(在68-86区域与GPMBP有显著差异)没有抑制作用。与GP68-86偶联的脾细胞能诱导深度无反应性,而与截短的GP68-84肽偶联的脾细胞则不能,这一事实也说明了耐受诱导的抗原特异性。有趣的是,抗原偶联细胞的从头抗原加工似乎并非必需,因为加入抗原加工抑制剂对疾病抑制没有影响。然而,碳二亚胺偶联试剂的使用对于无反应性的诱导至关重要,因为无论其存在与否,基本等量的¹²⁵I标记的MBP都能结合,但只有在MBP和碳二亚胺同时存在的情况下孵育的脾细胞才能抑制疾病的临床表达。因此,抗原特异性耐受是抑制大鼠EAE模型中临床疾病表达的有效手段,也是确定致脑炎性T细胞精细表位特异性的有力工具。